Key statistics
On Monday, Nicox SA (NXOA:FRA) closed at 0.4295, 164.15% above the 52 week low of 0.1626 set on May 23, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 0.4085 |
|---|---|
| High | 0.4295 |
| Low | 0.4085 |
| Bid | 0.4295 |
| Offer | 0.529 |
| Previous close | 0.4335 |
| Average volume | 0.00 |
|---|---|
| Shares outstanding | 88.44m |
| Free float | 81.62m |
| P/E (TTM) | -- |
| Market cap | 42.76m EUR |
| EPS (TTM) | -0.3657 EUR |
Data delayed at least 15 minutes, as of Mar 02 2026 20:47 GMT.
More ▼
Announcements
- Nicox Highlights Positive NCX 470 Phase 3 Data Confirming Therapeutic Profile at the 2026 American Glaucoma Society Annual Meeting
- Nicox présente des données de Phase 3 positives confirmant le profil thérapeutique de NCX 470 lors du congrès annuel 2026 de l’American Glaucoma Society (AGS)
- Nicox Announces Positive Feedback from pre-NDA Meeting with U.S. FDA for NCX 470
- Nicox annonce une réunion pré-NDA positive avec la FDA américaine pour NCX 470
- Nicox confirme son éligibilité au PEA-PME
- Nicox : Présentation des données des études de Phase 3 de NCX 470 au congrès annuel 2026 de l’American Glaucoma Society (AGS)
- Nicox to Present Data from NCX 470 Phase 3 Studies at American Glaucoma Society (AGS) Annual Meeting 2026
- Nicox Announces Conference Attendance in H1 2026 and Upcoming Scientific Data Presentations
- Nicox annonce sa participation à des congrès au premier semestre 2026 et la présentation prochaine de données scientifiques
- Nicox Announces Complete Repayment of Kreos Capital Debt and Extends Cash Runway Beyond 2027 with New Additional Financing
More ▼
